Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,700,505.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $494.79, for a total value of $4,700,505.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $160,531,151.97. This trade represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Trading Down 1.6%

Shares of NASDAQ UTHR opened at $489.42 on Thursday. The business has a 50-day moving average of $513.20 and a 200-day moving average of $540.55. The firm has a market capitalization of $20.99 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a 12 month low of $409.07 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the business posted $6.41 earnings per share. On average, analysts predict that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on UTHR. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada dropped their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. QRG Capital Management Inc. boosted its position in United Therapeutics by 3.5% during the second quarter. QRG Capital Management Inc. now owns 3,476 shares of the biotechnology company’s stock valued at $1,883,000 after buying an additional 116 shares during the period. Envestnet Portfolio Solutions Inc. increased its holdings in shares of United Therapeutics by 1.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,445 shares of the biotechnology company’s stock worth $1,867,000 after buying an additional 60 shares during the period. Andra AP fonden increased its holdings in shares of United Therapeutics by 33.5% in the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after buying an additional 8,760 shares during the period. Security National Bank of SO Dak bought a new stake in shares of United Therapeutics in the 2nd quarter valued at about $179,000. Finally, Talon Private Wealth LLC lifted its stake in shares of United Therapeutics by 31.8% in the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company’s stock valued at $3,659,000 after acquiring an additional 1,630 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.